Bexarotene

It has been used to investigate its effects on the changes in renal cardiac hepatic and pulmonary expressionactivity of inducible nitric oxide synthase (iNOS) and CYP4F6 to study its potential impurities in drug substances and drug products[6]

For R&D use onlynot for drug household or other uses.

Bexarotene (brand name Targretin) is an antineoplastic (anti-cancer) agent approved by the U.S.Food and Drug Administration (FDA) (in late 1999) and the European Medicines Agency (EMA) (early 2001) for use as a treatment for cutaneous T cell lymphoma (CTCL). It is a third-generation retinoid.